WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company, announced the granting of non-qualified stock options to purchase 134,000 shares of its common stock to two new employees under its 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.65 per share, reflecting the closing price on August 1, 2025. Each option has a ten-year term, with 25% vesting on the first anniversary of employment commencement and the remaining 75% vesting in 36 equal monthly installments, contingent on continued service. These grants comply with Nasdaq Listing Rule 5635(c)(4).
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。